Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
Top Page
Structure Therapeutics, Inc. Sponsored ADR
(NASDAQ:GPCR)
Select Model
Select Model
Rating:57Neutral
Price Target:
$55.00
▲(3.34% Upside)
Action:ReiteratedDate:04/15/26
The score is driven primarily by solid balance-sheet strength and positive clinical/operational catalysts, offset by the highest-risk factor of continued pre-revenue status with expanding losses and steep cash burn. Technicals and valuation are neutral-to-slightly negative and do not meaningfully improve the risk/reward profile near term.
Positive Factors
Balance-sheet strength
Low leverage and a materially expanded equity base provide durable financial flexibility to fund multi-year Phase 3 programs, pursue partnerships or M&A, and absorb trial setbacks without immediate solvency pressure. This supports execution through clinical inflection points.
Negative Factors
Pre-revenue with widening losses
No product revenue and materially expanding net losses mean the company depends on external funding to sustain operations. Over time this raises dilution risk, pressures timelines if financing tightens, and creates reliance on clinical success to generate future commercial cash flow.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet strength
Low leverage and a materially expanded equity base provide durable financial flexibility to fund multi-year Phase 3 programs, pursue partnerships or M&A, and absorb trial setbacks without immediate solvency pressure. This supports execution through clinical inflection points.
Read all positive factors
Structure Therapeutics, Inc. Sponsored ADR (GPCR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.84B
Dividend YieldN/A
Average Volume (3M)999.01K
Price to Earnings (P/E)31.2
Beta (1Y)1.27
Revenue GrowthN/A
EPS Growth-64.91%
CountryUS
Employees163
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.17
Shares Outstanding70,841,810
10 Day Avg. Volume1,032,151
30 Day Avg. Volume999,014
Financial Highlights & Ratios
PEG Ratio-11.37
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-18.23
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.31K
Enterprise Value/Ebitda-14.38
Forecast
1Y Price Target
$108.34Price Target Upside103.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-1.52
Revenue Forecast (FY)$6.67M
Structure Therapeutics, Inc. Sponsored ADR Business Overview & Revenue Model
Company Description
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biase...
How the Company Makes Money
Revenue information that clearly specifies how Structure Therapeutics currently makes money (e.g., product sales, recurring service revenue, or disclosed material collaboration/licensing income) is not available in the provided prompt. null...
Structure Therapeutics, Inc. Sponsored ADR Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
82
Very Positive
Cash Flow
26
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.90M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -136.79M | -157.24M | -102.48M | -52.28M | -37.62M |
| Net Income | -141.20M | -122.53M | -89.62M | -51.32M | -40.01M |
Balance Sheet | |||||
| Total Assets | 1.58B | 903.33M | 482.02M | 97.84M | 111.16M |
| Cash, Cash Equivalents and Short-Term Investments | 1.45B | 883.52M | 467.32M | 90.84M | 107.31M |
| Total Debt | 6.49M | 3.86M | 5.45M | 260.00K | 621.00K |
| Total Liabilities | 67.54M | 38.49M | 29.05M | 212.99M | 175.89M |
| Stockholders Equity | 1.52B | 864.84M | 452.97M | -115.14M | -64.73M |
Cash Flow | |||||
| Free Cash Flow | -225.81M | -117.93M | -81.66M | -46.27M | -33.37M |
| Operating Cash Flow | -222.20M | -116.64M | -79.49M | -46.12M | -32.16M |
| Investing Cash Flow | 89.80M | -358.91M | -268.34M | -62.11M | 17.86M |
| Financing Cash Flow | 762.52M | 515.26M | 451.53M | 29.01M | 103.25M |
Structure Therapeutics, Inc. Sponsored ADR Technical Analysis
Neutral
53.22
Price Trends
60.86
Negative
62.31
Negative
42.92
Positive
Market Momentum
-1.52
Negative
47.33
Neutral
71.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GPCR, the sentiment is Neutral. The current price of 53.22 is above the 20-day moving average (MA) of 50.80, below the 50-day MA of 60.86, and above the 200-day MA of 42.92, indicating a neutral trend. The MACD of -1.52 indicates Negative momentum. The RSI at 47.33 is Neutral, neither overbought nor oversold. The STOCH value of 71.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GPCR.
Structure Therapeutics, Inc. Sponsored ADR Risk Analysis
Structure Therapeutics, Inc. Sponsored ADR disclosed 103 risk factors in its most recent earnings report. Structure Therapeutics, Inc. Sponsored ADR reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Structure Therapeutics, Inc. Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $1.94B | -12.03 | -26.00% | ― | 116.21% | 43.93% | |
58 Neutral | $2.07B | -273.00 | -2.05% | ― | 1128.17% | ― | |
57 Neutral | $3.84B | 31.19 | -14.55% | ― | ― | -64.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.14B | -6.38 | -206.62% | ― | 597.19% | 0.45% |
* Healthcare Sector Average
GPCR
Structure Therapeutics, Inc. Sponsored ADR
53.22
34.32
181.59%
SNDX
Syndax Pharmaceuticals
24.43
13.10
115.62%
ZYME
Zymeworks
26.98
16.04
146.62%
STOK
Stoke Therapeutics
35.86
28.11
362.71%
Structure Therapeutics, Inc. Sponsored ADR Corporate Events
Business Operations and StrategyExecutive/Board Changes
Structure Therapeutics Appoints Matthew Lang as Chief Operating Officer
Positive
Apr 15, 2026
On April 14, 2026, Structure Therapeutics announced the appointment of Matthew Lang, J.D. as Chief Operating Officer and General Counsel, bringing more than 15 years of executive leadership across global biopharmaceutical companies. Lang’s b...
Business Operations and StrategyProduct-Related Announcements
Structure Therapeutics Reports Strong Phase 2 Obesity Drug Results
Positive
Mar 16, 2026
On March 16, 2026, Structure Therapeutics reported positive topline results from its Phase 2 ACCESS II trial of aleniglipron, showing statistically significant placebo-adjusted mean weight loss of 16.3% at 180 mg and 16.0% at 240 mg over 44 weeks,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.